Publications
Detailed Information
Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Hyejin | - |
dc.contributor.author | Choi, Soo Young | - |
dc.contributor.author | Kee, Kyung-Mi | - |
dc.contributor.author | Kim, Soo-Hyun | - |
dc.contributor.author | Yang, Seon-Young | - |
dc.contributor.author | Jung, Su Young | - |
dc.contributor.author | Noh, Hayeon | - |
dc.contributor.author | Zang, Dae Young | - |
dc.contributor.author | Kim, Dong-Wook | - |
dc.contributor.author | Lee, Jang Ik | - |
dc.date.accessioned | 2023-10-30T02:00:59Z | - |
dc.date.available | 2023-10-30T02:00:59Z | - |
dc.date.created | 2020-07-01 | - |
dc.date.created | 2020-07-01 | - |
dc.date.created | 2020-07-01 | - |
dc.date.issued | 2020-03 | - |
dc.identifier.citation | International Journal of Hematology, Vol.111 No.3, pp.417-426 | - |
dc.identifier.issn | 0925-5710 | - |
dc.identifier.uri | https://hdl.handle.net/10371/195980 | - |
dc.description.abstract | Safety and efficacy outcomes of imatinib treatment were evaluated using extensive clinical data collected from a total of 1003 patients with newly diagnosed chronic myeloid leukemia in chronic phase between 2001 and 2018. By 12 months of imatinib treatment at a fixed dose of 400 mg/day, 45.4% of patients experienced at least one type of dose-limiting toxicities (DLTs). The DLTs that frequently occurred first were thrombocytopenia (40.0%), neutropenia/leukopenia (14.3%) and dermatological reactions (12.1%). Patients with lighter body weight (<= 64 kg) and older age (> 43 years) experienced a markedly higher occurrence of first DLTs by 12 months than heavier and younger patients (57.9% vs. 30.1%, p < 0.001). On the other hand, 38.9% of patients achieved major molecular response (MMR) at 12 months at the fixed dose. Female patients achieved a greater rate of MMR than male patients (45.6% vs. 35.5%, p = 0.028). In conclusion, patients with light weight and old age are more vulnerable to DLTs, whereas female patients gain more efficacy benefit at the fixed dose. The authors suggest that the initial dose of imatinib should be reduced to 300 mg/day or lower for patients vulnerable to DLTs to diminish the risk of DLTs without compromising the achievement of MMR. | - |
dc.language | 영어 | - |
dc.publisher | Japanese Society of Hematology | - |
dc.title | Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12185-019-02805-9 | - |
dc.citation.journaltitle | International Journal of Hematology | - |
dc.identifier.wosid | 000503713700001 | - |
dc.identifier.scopusid | 2-s2.0-85077018031 | - |
dc.citation.endpage | 426 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 417 | - |
dc.citation.volume | 111 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Lee, Jang Ik | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITORS | - |
dc.subject.keywordPlus | BODY-MASS INDEX | - |
dc.subject.keywordPlus | CHRONIC MYELOGENOUS LEUKEMIA | - |
dc.subject.keywordPlus | CHRONIC-PHASE | - |
dc.subject.keywordPlus | MOLECULAR RESPONSE | - |
dc.subject.keywordPlus | CLINICAL-RESPONSE | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | PLASMA-LEVELS | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | CML | - |
dc.subject.keywordAuthor | Imatinib | - |
dc.subject.keywordAuthor | Dose individualization | - |
dc.subject.keywordAuthor | Chronic myeloid leukemia | - |
dc.subject.keywordAuthor | Dose-limiting toxicity | - |
dc.subject.keywordAuthor | Major molecular response | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.